Pregnancy and the endocrine regulation of the baroreceptor reflex.
The purpose of this review is to delineate the general features of endocrine regulation of the baroreceptor reflex, as well as specific contributions during pregnancy. In contrast to the programmed changes in baroreflex function that occur in situations initiated by central command (e.g., exercise or stress), the complex endocrine milieu often associated with physiological and pathophysiological states can influence the central baroreflex neuronal circuitry via multiple sites and mechanisms, thereby producing varied changes in baroreflex function. During pregnancy, baroreflex gain is markedly attenuated, and at least two hormonal mechanisms contribute, each at different brain sites: increased levels of the neurosteroid 3alpha-hydroxy-dihydroprogesterone (3alpha-OH-DHP), acting in the rostral ventrolateral medulla (RVLM), and reduced actions of insulin in the forebrain. 3alpha-OH-DHP appears to potentiate baroreflex-independent GABAergic inhibition of premotor neurons in the RVLM, which decreases the range of sympathetic nerve activity that can be elicited by changes in arterial pressure. In contrast, reductions in the levels or actions of insulin in the brain blunt baroreflex efferent responses to increments or decrements in arterial pressure. Although plasma levels of angiotensin II are increased in pregnancy, this is not responsible for the reduction in baroreflex gain, although it may contribute to the increased level of sympathetic nerve activity in this condition. How these different hormonal effects are integrated within the brain, as well as possible interactions with additional potential neuromodulators that influence baroreflex function during pregnancy and other physiological and pathophysiological states, remains to be clearly delineated.
Brooks
Virginia L
VL
Dept. of Physiology and Pharmacology, L-334, Oregon Health & Science Univ., 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. brooksv@ohsu.edu
Dampney
Roger A L
RA
Heesch
Cheryl M
CM
D000804:Angiotensin II / Q000378:metabolism; D000818:Animals; D017704:Baroreflex; D001794:Blood Pressure; D002319:Cardiovascular System / Q000294:innervation*; D004703:Endocrine System / Q000378:metabolism*; D005260:Female; D006339:Heart Rate; D006801:Humans; D006908:Hydroxyprogesterones / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance; D008526:Medulla Oblongata / Q000378:metabolism; D009434:Neural Pathways / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000378:metabolism / Q000503:physiopathology; D016548:Prosencephalon / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000378:metabolism*
D006908:Hydroxyprogesterones; D007328:Insulin; D000804:Angiotensin II; D009569:Nitric Oxide